Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

DNA repair deficiency in peripheral blood lymphocytes of endometrial cancer patients with a family history of cancer

Authors: Lyubov Buchynska, Olga Brieieva, Nadiia Glushchenko, Ludmila Vorobyova, Olena Bilyk

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Individual susceptibility to endogenous and/or exogenous DNA damage depends on DNA repair efficiency and can be evaluated using the comet assay with bleomycin as genotoxic agent. The aim of the study was to evaluate baseline and bleomycin-induced DNA damage and DNA repair capacity in peripheral blood lymphocytes (PBLs) of endometrial cancer (EC) patients considering a family history of cancer.

Methods

DNA damage was analyzed in PBLs of 45 EC patients compared to a control group of 10 healthy women, using the comet assay. The level of DNA damage was determined by the% tail DNA.

Results

The level of baseline DNA damage in PBLs of EC patients was significantly higher (% DNA in tail 9.31 ± 15.32) than in healthy women (% DNA in tail 3.41 ± 4.71) (P <0.01). PBLs of EC patients repaired less bleomycin-induced DNA damage (removed% DNA in tail 63.94 ± 20.92) than PBLs of healthy individuals (removed% DNA in tail 80.24 ± 3.03) (P <0.001). Efficiency of DNA repair in PBLs of EC patients depended on the family history of cancer. The amount of restored damaged DNA was significantly lower (removed% DNA in tail 36.24 ± 14.05%) in EC patients with a family history of cancer compared to patients with sporadic EC (removed% DNA in tail 64.91 ± 19.36%) (P <0.004).

Conclusions

Lymphocytes of EC patients are characterized by an increased basal level of DNA damage as well as deficiency in DNA repair. DNA repair is less efficient in PBLs of EC patients with a family history of cancer compared to patients with sporadic cancer.
Appendix
Available only for authorised users
Literature
1.
Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell. 2011, 144: 646-674. 10.1016/j.cell.2011.02.013.CrossRefPubMed
2.
Pikor L, Thu K, Vucic E, Lam W: The detection and implication of genome instability in cancer. Cancer Metastasis Rev. 2013, doi:10.1007/s10555-013-9429-5
3.
Aguilera A, Gómez-González B: Genome instability: a mechanistic view of its causes and consequences. Nat Rev Genet. 2008, 9: 204-217. 10.1038/nrg2268.CrossRefPubMed
4.
Orlow I, Park BJ, Mujumdar U, Patel H, Siu-Lau P, Clas BA, Downey R, Flores R, Bains M, Rizk N, Dominguez G, Jani J, Berwick M, Begg CB, Kris MG, Rusch VW: DNA damage and repair capacity in patients with lung cancer: prediction of multiple primary tumors. J Clin Oncol. 2008, 26: 3560-3566. 10.1200/JCO.2007.13.2654.CrossRefPubMedPubMedCentral
5.
Spitz MR, Wei Q, Dong Q, Amos CI, Wu X: Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol Biomarkers Prev. 2003, 12: 689-698.PubMed
6.
Krupa R, Sobczuk A, Poplawski T, Wozniak K, Blasiak J: DNA damage and repair in endometrial cancer in correlation with the hOGG1 and RAD51 genes polymorphism. Mol Biol Rep. 2011, 38 (2): 1163-70. 10.1007/s11033-010-0214-z.CrossRefPubMed
7.
Hille A, Hofman-Hüther H, Kühnle E, Wilken B, Rave-Fränk M, Schmidberger H, Virsik P: Spontaneous and radiation-induced chromosomal instability and persistence of chromosome aberrations after radiotherapy in lymphocytes from prostate cancer patients. Radiat Environ Biophys. 2010, 49: 27-37. 10.1007/s00411-009-0244-x.CrossRefPubMed
8.
Walczak A, Rusin P, Dziki L, Zielinska-Blizniewska H, Olszewski J, Majsterek I: Evaluation of DNA double strand breaks repair efficiency in head and neck cancer. DNA Cell Biol. 2012, 31: 298-305. 10.1089/dna.2011.1325.CrossRefPubMed
9.
Saha DT, Davidson BJ, Wang A, Pollock AJ, Orden RA, Goldman R: Quantification of DNA repair capacity in whole blood of patients with head and neck cancer and healthy donors by comet assay. Mutat Res. 2008, 650: 55-62. 10.1016/j.mrgentox.2007.10.004.CrossRefPubMed
10.
Burgaz S, Coskun E, Demircigil GC, Kocabas NA, Cetindag F, Sunter O, Edinsel H: Micronucleus frequencies in lymphocytes and buccal epithelial cells from patients having head and neck cancer and their first-degree relatives. Mutagenesis. 2011, 26: 351-356. 10.1093/mutage/geq101.CrossRefPubMed
11.
Santos RA, Teixeira AC, Mayorano MB, Carrara HH, Andrade JM, Takahashi CS: Basal levels of DNA damage detected by micronuclei and comet assays in untreated breast cancer patients and healthy women. Clin Exp Med. 2010, 10: 87-92. 10.1007/s10238-009-0079-4.CrossRefPubMed
12.
Smith TR, Miller MS, Lohman KK, Case LD, Hu JJ: DNA damage and breast cancer risk. Carcinogenesis. 2003, 24: 883-889. 10.1093/carcin/bgg037.CrossRefPubMed
13.
Roy SK, Trivedi AH, Bakshi SR, Patel SJ, Shukla PH, Bhatavdekar JM, Patel DD, Shah PM: Bleomycin-induced chromosome damage in lymphocytes indicates inefficient DNA repair capacity in breast cancer families. J Exp Clin Cancer Res. 2000, 19: 169-173.PubMed
14.
Nesina IP, Polishchuk LZ, Oliynichenko PI: The determination of chromosomal fragile sites in the peripheral blood lymphocytes of the patients with colorectal cancer in consideration of oncopathology aggregation in family history. Cytol Genet. 2000, 34: 3-10. Russian
15.
Lancaster JM, Powell CB, Kauff ND, Cass I, Chen LM, Lu KH, Mutch DG, Berchuck A, Karlan BY, Herzog TJ: Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer dispositions. Gynecol Oncol. 2007, 107: 159-162. 10.1016/j.ygyno.2007.09.031.CrossRefPubMed
16.
Akulenko LV: Hereditary cancer of reproductive system of women. Oncogynecology. 2012, 1: 24-31. Russian
17.
Chudina AP: Lynch syndrome and sporadic colorectal cancer: clinical and genealogical features. Russ Can J Oncol. 2012, 3: 11-14. Russian
18.
Chekhun WF, Polishchuk LZ, Buchynska LH: Clinical oncogenetics. Genetic Medicine. Edited by: Zaporozhan BH. 2008, Odessa: Odessa Medical University, 222-262. Russian
19.
Dusinska M, Collins AR: The comet assay in human biomonitoring: gene-environment interactions. Mutagenesis. 2008, 23: 191-205. 10.1093/mutage/gen007.CrossRefPubMed
20.
Schmezer P, Rajaee-Behbahani N, Risch A, Thiel S, Rittgen W, Drings P, Dienemann H, Kayser KW, Schulz V, Bartsch H: Rapid screening assay for mutagen sensitivity and DNA repair capacity in human peripheral blood lymphocytes. Mutagenesis. 2001, 16: 25-30. 10.1093/mutage/16.1.25.CrossRefPubMed
21.
Kurzawa-Zegota M, Najafzadeh M, Baumgartner A, Anderson D: The protective effect of the flavonoids on food-mutagen-induced DNA damage in peripheral blood lymphocytes from colon cancer patients. Food Chem Toxicol. 2012, 50: 124-129. 10.1016/j.fct.2011.08.020.CrossRefPubMed
22.
Najafzadeh M, Baumgartner A, Gopalan R, Davies JB, Wright A, Reynolds PD, Anderson D: In vitro sensitivities to UVA of lymphocytes from patients with colon and melanoma cancers and precancerous states in the micronucleus and the Comet assays. Mutagenesis. 2012, 27: 351-357. 10.1093/mutage/ger087.CrossRefPubMed
23.
Kryston TB, Georgiev AB, Pissis P, Georgakilas AG: Role of oxidative stress and DNA damage in human carcinogenesis. Mutat Res. 2011, 711: 193-201. 10.1016/j.mrfmmm.2010.12.016.CrossRefPubMed
24.
Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature. 2008, 454: 436-444. 10.1038/nature07205.CrossRefPubMed
25.
Atukeren P, Yavuz B, Soydinc HO, Purisa S, Camlica H, Gumustas MK, Balcioglu I: Variations in systemic biomarkers of oxidative/nitrosative stress and DNA damage before and during the consequent two cycles of chemotherapy in breast cancer patients. Clin Chem Lab Med. 2010, 48: 1487-1495.CrossRefPubMed
26.
Vulimiri SV, Wu X, Baer-Dubowska W, De Andrade M, Detry M, Spitz MR, DiGiovanni J: Analysis of aromatic DNA adducts and 7,8-dihydro-8-oxo-2′ deoxyguanosine in lymphocyte DNA from a case-control study of lung cancer involving minority populations. Mol Carcinog. 2000, 1: 34-47.CrossRef
27.
Obtulowicz T, Swoboda M, Speina E, Gackowski D, Rozalski R, Siomek A, Janik J, Janowska B, Ciesla JM, Jawien A, Banaszkiewicz Z, Guz J, Dziaman T, Szpila A, Olinski R, Tudek B: Oxidative stress and 8-oxoguanine repair are enhanced in colon adenoma and carcinoma patients. Mutagenesis. 2010, 25: 463-471. 10.1093/mutage/geq028.CrossRefPubMed
Metadata
Title
DNA repair deficiency in peripheral blood lymphocytes of endometrial cancer patients with a family history of cancer
Authors
Lyubov Buchynska
Olga Brieieva
Nadiia Glushchenko
Ludmila Vorobyova
Olena Bilyk
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-765

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Btbd7 contributes to reduced E-cadherin expression and predicts poor prognosis in non-small cell lung cancer

Research article

T cells but not NK cells are associated with a favourable outcome for resected colorectal liver metastases

Research article

Dissecting the signaling pathways associated with the oncogenic activity of MLK3 P252H mutation

Research article

Role of intracellular and extracellular annexin A1 in migration and invasion of human pancreatic carcinoma cells

Research article

Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis

Research article

The novel arylindolylmaleimide PDA-66 displays pronounced antiproliferative effects in acute lymphoblastic leukemia cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits